Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 4/20 | 0.44 |
| ▸ | DPP4 | P27487 | 5/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 5/20 | 0.35 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.32 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23715196 | 0.95 | MME (0.41) | MMEDPP4P2RX7HTTCNR2 | |
| SCHEMBL13941597 | 0.91 | — | — | |
| SCHEMBL15461395 | 0.81 | DPP4 (0.40) | MMEDPP4ALDH1A1 | |
| SCHEMBL7724887 | 0.81 | CYP4F2 (0.36) | MMEP2RX7HTTALDH1A1CYP4F2 | |
| SCHEMBL2847321 | 0.80 | ALDH1A1 (0.36) | MMEP2RX7HTTALDH1A1 | |
| SCHEMBL5220339 | 0.80 | HTT (0.38) | MMEP2RX7HTTALDH1A1 | |
| SCHEMBL7400386 | 0.79 | CYP1A2 (0.34) | MME | |
| SCHEMBL9104945 | 0.79 | MME (0.45) | MMEDPP4HTTCNR2CACNA1H | |
| SCHEMBL12846960 | 0.78 | MME (0.45) | MMEDPP4HTTCNR2CACNA1H | |
| SCHEMBL3373260 | 0.78 | CYP2C19 (0.42) | MMEP2RX7HTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011000945-A2 | AMINOALKAMIDES FOR USE IN THE TREATMENT OF INFLAMMATORY, DEGENERATIVE OR DEMYELINATING DISEASES OF THE CNS | NENSIUS RESEARCH A/S (DK) | 2011-01-06 | — | — | WO | claimed |
| EP-2863916-B1 | SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (SYK) INHIBITORS | MERCK SHARP & DOHME (US) | 2018-07-18 | — | — | EP | disclosed |
| WO-2017040450-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-09 | — | — | WO | disclosed |
| US-9376418-B2 | Substituted pyridine spleen tyrosine kinase (SYK) inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-06-28 | — | — | US | disclosed |
| US-20150148327-A1 | SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (SYK) INHIBITORS | MERCK CANADA INC. (CA) | 2015-05-28 | — | — | US | disclosed |
| EP-2342191-B1 | AROMATIC NITROGEN-CONTAINING 6-MEMBERED RING COMPOUNDS AND THEIR USE | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-03-20 | — | — | EP | disclosed |
| US-8198311-B2 | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-06-12 | — | — | US | disclosed |
| US-8067442-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2011-11-29 | — | — | US | disclosed |
| US-20110166135-A1 | AROMATIC NITROGEN-CONTAINING 6-MEMBERED RING COMPOUNDS AND THEIR USE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-07-07 | — | — | US | disclosed |
| US-20110166135-A1 | AROMATIC NITROGEN-CONTAINING 6-MEMBERED RING COMPOUNDS AND THEIR USE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-07-07 | — | — | US | disclosed |
| US-7745641-B2 | Nitrogen-containing heterocyclic compound | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-06-29 | — | — | US | disclosed |
| US-20100081658-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | ROCHE PALO ALTO LLC | 2010-04-01 | — | — | US | disclosed |
| US-20100075961-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2010-03-25 | — | — | US | disclosed |
| WO-2010030027-A1 | AROMATIC NITROGEN-CONTAINING 6-MEMBERED RING COMPOUNDS AND THEIR USE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-03-18 | — | — | WO | disclosed |
| EP-2108642-A1 | JAK INHIBITOR | Kyowa Hakko Kirin Co., Ltd. (JP) | 2009-10-14 | — | — | EP | disclosed |
| US-20090054407-A1 | Nitrogen-containing heterocyclic compound | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-02-26 | — | — | US | disclosed |
| US-20090054407-A1 | Nitrogen-containing heterocyclic compound | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-02-26 | — | — | US | disclosed |
| US-20080194549-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-08-14 | — | — | US | disclosed |
| WO-2008057857-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ϰB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-15 | — | — | WO | disclosed |
| CN-101146530-A | 3, 4-substituted pyrrolidine derivatives for the treatment of hypertension | NOVARTIS AG (CH) | 2008-03-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075961-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | NFRKB, NR0B1, NFKB2 | MME 3919/4885DPP4 3485/4885P2RX7 3146/4885 |
| US-20090054407-A1 | Nitrogen-containing heterocyclic compound | NR4A1, NR5A2, PRMT8 | MME 3439/4885DPP4 3208/4885P2RX7 1210/4885 |
| US-20080194549-A1 | Organic Compounds | REN, ACE, OTC | MME 90/4885DPP4 62/4885P2RX7 1611/4885 |
| US-20110166135-A1 | AROMATIC NITROGEN-CONTAINING 6-MEMBERED RING COMPOUNDS AND THEIR USE | PDE10A, PDE3A, PDE3B | MME 1884/4885DPP4 751/4885P2RX7 248/4885 |
| US-20150148327-A1 | SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (SYK) INHIBITORS | SYK, BTK, LYN | MME 3558/4885DPP4 3633/4885P2RX7 317/4885 |
| US-20100081658-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | EIF2AK2, POLR2A, HCCS | MME 1326/4885DPP4 1906/4885P2RX7 2523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.